Scarica l'app Stockscreener
33.73
1.78%
-0.61
Dopo l'orario di chiusura:
33.73
Precedente Chiudi:
$34.34
Aprire:
$34.33
Volume 24 ore:
1.72M
Relative Volume:
1.11
Capitalizzazione di mercato:
$4.96B
Reddito:
$813.46M
Utile/perdita netta:
$-365.74M
Rapporto P/E:
-11.75
EPS:
-2.87
Flusso di cassa netto:
$-375.18M
1 W Prestazione:
-13.25%
1M Prestazione:
-14.99%
6M Prestazione:
-9.60%
1 anno Prestazione:
-31.12%
Intervallo 1D:
$33.63
$34.79
Intervallo di 1 settimana:
$33.63
$38.77
Portata 52W:
$33.63
$54.44
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| IONS | 33.73 | 4.96B | 813.46M | -365.74M | -375.18M | -2.87 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks - Yahoo Finance
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Large Increase in Short Interest - MarketBeat
RSI Alert: Ionis Pharmaceuticals (IONS) Now Oversold - Nasdaq
BB Biotech AG Adjusts Stake in Ionis Pharmaceuticals - GuruFocus.com
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month Low on Insider Selling - MarketBeat
Insider Sale: CEO Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com
Ionis Pharmaceuticals EVP Eric Swayze sells shares worth $45,277 - Investing.com
Ionis Pharmaceuticals director Joseph Loscalzo sells shares for $511,426 - Investing.com
Ionis Pharmaceuticals CEO Brett Monia sells $252,294 in stock - Investing.com
T. Rowe Price Investment Management, Inc. Expands Stake in Ionis Pharmaceuticals Inc - GuruFocus.com
Piper Sandler Issues Pessimistic Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer - cnhinews.com
Baillie Gifford & Co. Sells 220,673 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year - Investing.com
Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma - The Globe and Mail
Acromegaly Market Forecasted to Surge in Coming Years, - openPR
Ionis Pharmaceuticals (NASDAQ:IONS) Downgraded by StockNews.com to "Sell" - MarketBeat
What is Leerink Partnrs' Forecast for IONS FY2024 Earnings? - MarketBeat
Wellington Management Group LLP Increases Stake in Ionis Pharmac - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2024 Earnings Call Transcript - Insider Monkey
FY2028 EPS Estimates for IONS Reduced by Leerink Partnrs - MarketBeat
ARK Investment Management LLC Buys 23,244 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus - MSN
Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Ionis to present at upcoming investor conferences - GuruFocus.com
FDA agrees to review Ionis’ donidalorsen as treatment for HAE - Angioedema News Today
Is there a 2024 Duloxetine recall? FDA flags 7,100+ bottles of generic Cymbalta antidepressants - AOL
Bristol Myers wins US FDA approval for new type of schizophrenia drug - AOL
Why Walgreens, CVS and Rite Aid are closing thousands of drug stores across America - AOL
Needham & Company LLC Reaffirms Buy Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - MarketBeat
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - AOL
Ionis announces design for Phase III trial of Angelman syndrome therapy - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo Finance
Ionis Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights
Ionis reaches agreement on phase 3 trial design for Angelman candidate - Seeking Alpha
Ionis Pharmaceuticals Beats on Revenue - The Motley Fool
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings: Revenue Surpa - GuruFocus.com
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? - The Motley Fool
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Ionis Pharmaceuticals: Q3 Earnings Snapshot - San Antonio Express-News
Ionis gears up for Phase 3 Angelman syndrome trial - Investing.com
Ionis gears up for Phase 3 Angelman syndrome trial By Investing.com - Investing.com UK
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Upcoming Opportunities in Hereditary Amyloidosis Market: - openPR
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Hold at StockNews.com - MarketBeat
Ionis' donidalorsen awaits FDA decision for HAE treatment - Investing.com India
FDA Sets Goal Date for Donidalorsen in HAE - Managed Healthcare Executive
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):